Skip to content
CancerIndex

Publication

Characteristics of lung cancers harboring NRAS mutations.

Authors not recorded

Clin Cancer Res2013PMID 23515407PMC3643999stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

Curated evidence

Evidence citing this paper (4)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
23515407
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
NRAS Q61K2
Selumetinib + TrametinibSubstitutesLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response2accepted
EID2907

Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations (one harboring Q61L, t… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

civic
〃Malignant Lung NeoplasmPredictiveDSupports Sensitivity Response3rejected
EID2908

NRAS mutations define a distinct subset of lung cancers (∼1%) with potential sensitivity to MEK inhibitors. Although NRAS mutations are more common in current/former smokers, the types of mutations ar… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

civic
NRAS Q61L1
Selumetinib + TrametinibSubstitutesLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response2submitted
EID3018

Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations and 5/6 were sensitivi… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

civic
NRAS Q61R1
Selumetinib + TrametinibSubstitutesLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response2submitted
EID3019

Of the 4,562 patients with lung cancers, 30 showed NRAS mutations, which corresponded to 9 different amino acid substitutions. Cell lines were developed for 6 of these mutations and 5/6 were sensitivi… (full text at CIViC)

PMID 23515407 · Ohashi et al., 2013 · Open in CIViC

civic